Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
Globe Newswire•01/10/2026•09:00 ET
0
Key Highlights
- ➤Legend Biotech (LEGN) launches annual ELITE grant program for multiple myeloma CAR-T innovation
- ➤Program awards grants in Emerging Educator and Emerging Innovator CAR-T categories
- ➤Applications remain open through November 20, 2026
- ➤Recipients will be notified in December 2026 and recognized in 2027
Expert Statements
Alan Bash, President, CARVYKTI
“At Legend Biotech, we believe that advancing the future of cellular therapy requires continued investment in the people and ideas that will shape the field.”
Alan Bash, President, CARVYKTI
“Through the ELITE Program, we are supporting the next generation of innovators and research that can improve care for patients living with multiple myeloma, while we advance our pursuit of a cure.”
Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma
BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program, an annual grant initiative designed to recognize and support early-career healthcare professionals advancing novel cell therapy approaches for the treatment of multiple myeloma. Applications are open through November 20, 2026.
Get started
Create a free account to read the full story.